Text Size
6 studies found for:    weill | Open Studies | "Pancreatic Neoplasms"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer
Conditions: Cholangiocarcinoma;   Pancreatic Cancer
Intervention: Device: Endoscopic bipolar radiofrequency probe (ENDOHPB)
2 Recruiting EUS-Guided ERCP Multicenter Registry
Conditions: Cholangiocarcinoma;   Pancreatic Cancer;   Bile Duct Cancer;   Biliary Stricture;   Biliary Obstruction;   Stent Obstruction;   Proximal Duct Stricture;   Distal Duct Stricture;   Ampullary Cancer;   Biliary Sphincter Stenosis;   Impacted Stones;   Chronic Pancreatitis;   Peri-ampullary Diverticula;   Altered Anatomy
Intervention: Procedure: EUS guided ERCP
3 Unknown † 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Conditions: Kidney Cancer;   Head and Neck Cancer;   Breast Cancer;   Non-small Cell Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Esophageal Cancer;   Gliomas
Intervention: Drug: 177Lu-J591
4 Recruiting Ph I Dose Escalation Study of Antibody-drug Conjugate IMMU-132 in Patients With Advanced Epithelial Cancers
Conditions: Advanced Epithelial Cancers;   Ovarian Cancer;   Prostate Cancer;   Lung Cancer;   Breast Cancer;   Gastric Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Hepatocellular Cancer
Intervention: Drug: IMMU-132
5 Recruiting Spectroscopy With Surface Coils and Decoupling
Conditions: Adrenal Cortical Cancer;   Brain Cancer;   Breast Cancer;   CNS Cancer;   Colon Cancer;   HEENT Cancer;   Hodgkin's Disease;   Kaposi's Sarcoma;   Liver Cancer;   Lung Cancer;   Non-Hodgkin's Lymphoma;   Ovarian Cancer;   Pancreatic Cancer;   Prostate Cancer;   Rectal Cancer;   Renal Cancer;   Sarcoma;   Squamous Cell Carcinoma;   Thyroid Cancer
Interventions: Device: Proton-decoupled 31P MRS at 1.5T;   Device: 1H Spectroscopy at 1.5T and 3T
6 Recruiting Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Endometrial Papillary Serous Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Ovarian Carcinosarcoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Papillary Serous Carcinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Alpha Cell Carcinoma;   Pancreatic Beta Islet Cell Adenoma;   Pancreatic Beta Islet Cell Carcinoma;   Pancreatic Delta Cell Adenoma;   Pancreatic Delta Cell Carcinoma;   Pancreatic G-cell Adenoma;   Pancreatic G-cell Carcinoma;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Regional Gastrointestinal Carcinoid Tumor;   Stage IIIA Endometrial Carcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Endometrial Carcinoma;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Endometrial Carcinoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma;   Uterine Carcinosarcoma
Interventions: Drug: temsirolimus;   Biological: bevacizumab
To Top

† Indicates status has not been verified in more than two years